Phil Febbo, M.D.

Febbo is in his present position since 2018, responsible for Illumina’s medical strategy to drive genomic testing into healthcare practice. Previously, he was CMO of Genomic Health and professor of medicine and urology at the University of California, San Francisco, where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer. He currently serves on the board of the American College of Medical Genetics and Genomics Foundation.

  • 2019 Fourth Quarter

Added to: Varian Medical Systems Inc. - Palo Alto, CA

Varian provides medical devices and software products for treating cancer. Revenues are $3 billion.